Table 1.
Venetoclax Toxicities
| Venetoclax Phase 150 | Venetoclax/Dexamethasone Phase 1/252 | Venetoclax/Bortezomib Phase 156 | Venetoclax/Bortezomib Phase 357 | |
|---|---|---|---|---|
| Patients | 66 | 51 | 66 | 193 |
| Nausea | 47% (3%) | 28% | 38% (5%) | 36% (3%) |
| Diarrhea | 36% (3%) | 35% | 46% (6%) | 58% (15%) |
| Constipation | 41% (0%) | 34% (0%) | ||
| Peripheral neuropathy | 33% (3%) | 30% (5%) | ||
| URI | 21% (2%) | 29% (2%) | ||
| Fatigue | 27% (5%) | 14% | 24% (0%) | 30% (5%) |
| Insomnia | 26% | 32% (5%) | 28% (2%) | |
| Hyperglycemia | 24% | 11% (7%) | ||
| Hypophosphatemia | 22% (3%) | |||
| Back pain | 21% (8%) | 20% (2%) | ||
| Vomiting | 21% (3%) | 19% (2%) | ||
| Thrombocytopenia | 32% (26%) | 18% (10%) | 39% (29%) | 26% (15%) |
| Neutropenia | 37% (21%) | 18% (10%) | 15% (14%) | 23% (18%) |
| Anemia | 23% (14%) | 20% (12%) | 27% (15%) | 26% (15%) |
| Lymphopenia | 18% (15%) | 28% (20%) | ||
| Pneumonia | 8% | 8% | 16% | |
| Sepsis | 5% | 10% | 5% | 3% |
| Tumor lysis syndrome | 3% |
Note: % all grades (% grade 3/4).
Abbreviation: URI, upper respiratory infection.